Cell fate regulation by gelsolin in human gynecologic cancers

Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer

(2012) Bradley J. Monk et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives

(2011) J. Sehouli et al.   ANNALS OF ONCOLOGY

Optimal treatment for relapsing ovarian cancer

(2010) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

Gelsolin, but not its cleavage, is required for TNF-induced ROS generation and apoptosis in MCF-7 cells

(2009) Qinxi Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

(2009) Maurie Markman et al.   GYNECOLOGIC ONCOLOGY

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET

Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein

(2009) M R Abedini et al.   ONCOGENE

Cisplatin Induces p53-Dependent FLICE-Like Inhibitory Protein Ubiquitination in Ovarian Cancer Cells

(2008) M. R. Abedini et al.   CANCER RESEARCH